PBX4 has been implicated as a potential novel onco-promoter in CRC, as evidenced by its overexpression, which increases cancer cell proliferation and upregulates the expression of markers of epithelial-mesenchymal transition (EMT) and angiogenesis (Martinou et al., 2022). This evidence concerns the gene PBX4 and colorectal carcinoma.